Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma

NCT06017297 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Sponsor decision and challenges in finding eligible participants

Conditions

Borderline Resectable Carcinoma
Biliary Tract Cancer

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab
DRUG: Gemcitabine
DRUG: Cisplatin
PROCEDURE: Surgical Resection

Sponsor

Georgetown University

Collaborators

[object Object]